Patent: 5,770,195
Summary for Patent: 5,770,195
| Title: | Monoclonal antibodies directed to the her2 receptor |
| Abstract: | A method of inhibiting growth of tumor cells which overexpress a growth factor receptor or growth factor by treatment of the cells with antibodies which inhibit the growth factor receptor function, is disclosed. A method of treating tumor cells with antibodies which inhibit growth factor receptor function, and with cytotoxic factor(s) such as tumor necrosis factor, is also disclosed. By inhibiting growth factor receptor functions tumor cells are rendered more susceptible to cytotoxic factors. |
| Inventor(s): | Robert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly |
| Assignee: | Genentech Inc |
| Application Number: | US08/447,517 |
| Patent Claims: | see list of patent claims |
Details for Patent 5,770,195
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | PERJETA | pertuzumab | Injection | 125409 | June 8, 2012 | ⤷ Start Trial | 2015-06-23 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
